A study measures the long-term downside of prostate cancer screening A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

Cleveland Clinic Abu Dhabi performs first-ever transcontinental robotic assisted focal therapy procedure for prostate cancer

Cleveland Clinic Abu Dhabi, in collaboration with experts from Cleveland Clinic in the U.S., performed the world’s first remotely conducted transcontinental robotic-assisted focal therapy for prostate cancer.

April 25, 2025

Vol.51 No.16

Clinical Roundup

Gene-based blood test for melanoma may detect early signs of cancer return

Monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer recurrence, a recent study led by researchers at NYU Langone Health and its Perlmutter Cancer Center shows.

April 18, 2025

Vol.51 No.15

Clinical Roundup

UCLA test predicts which prostate cancer patients are most likely to develop long-term side effects from radiation therapy

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have validated a test that can accurately predict which patients with prostate cancer are at higher risk of developing long-lasting urinary side effects after receiving radiation therapy.

April 11, 2025

Vol.51 No.14

Drugs & Targets

Exact Sciences launches the Cologuard Plus test for colorectal cancer screening

Exact Sciences Corp. announced the launch of Cologuard Plus, the most accurate noninvasive colorectal cancer screening test reported in studies to date. FDA-approved for average-risk patients 45+ and covered by Medicare, the Cologuard Plus test detects 95% of colorectal cancers at 94% specificity in the U.S. screening population.

April 04, 2025

Vol.51 No.13

Clinical Roundup

Pandemic caused temporary disruptions in CRC screening and minimal impact on diagnosis, two studies show

Two recent studies by researchers from Regenstrief Institute and the Indiana University School of Medicine explore the effect of the pandemic on colorectal cancer screening tests and diagnostic colonoscopies in central Indiana.

March 28, 2025

Vol.51 No.12

Drugs & Targets

FDA approves prostate cancer imaging agent Gozellix

FDA approved Gozellix (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), a next-generation PSMA-PET imaging agent for prostate cancer.

March 28, 2025

Vol.51 No.12

A study measures the long-term downside of prostate cancer screening

A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

YOU MAY BE INTERESTED IN

Cleveland Clinic Abu Dhabi performs first-ever transcontinental robotic assisted focal therapy procedure for prostate cancer

Gene-based blood test for melanoma may detect early signs of cancer return

UCLA test predicts which prostate cancer patients are most likely to develop long-term side effects from radiation therapy

Exact Sciences launches the Cologuard Plus test for colorectal cancer screening

Pandemic caused temporary disruptions in CRC screening and minimal impact on diagnosis, two studies show

FDA approves prostate cancer imaging agent Gozellix

Renew today!

Subscriber content

Never miss an issue!

Login